TITLE

AACR Roundup

PUB. DATE
April 2011
SOURCE
BioWorld Today;4/5/2011, Vol. 22 Issue 65, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the preclinical data presented by Lorus Therapeutics Inc. at the annual meeting of the American Association for Cancer Research (AACR) on lead small molecule LOR-253 as an inhibitor of growth of non-small-cell lung cancer in both in vitro and animal models.
ACCESSION #
59851605

 

Related Articles

  • AACR 2012.  // BioWorld Today;4/4/2012, Vol. 23 Issue 65, p8 

    The article reports that LOR-253 drug from Lorus Therapeutics Inc. combined with docetaxel resulted to significant and synergistic anticancer activity among patients with non-small-cell lung cancer (NSCLC) based on preclinical data.

  • Cancer: Targeting LSD1 in small cell lung cancer. Crunkhorn, Sarah // Nature Reviews Drug Discovery;Sep2015, Vol. 14 Issue 9, p602 

    The article reports on the discovery of the GSK2879552, an irreversible lysine-specific histone demethylase 1A (LSD1) inactivator, that prevents the proliferation of the cell lines of small cell lung cancer.

  • 4β-Hydroxywithanolide E from Physalis peruviana (golden berry) inhibits growth of human lung cancer cells through DNA damage, apoptosis and G2/M arrest. Ching-Yu Yen; Chien-Chih Chiu; Fang-Rong Chang; Jeff Yi-Fu Chen; Chi-Ching Hwang; You-Cheng Hseu; Hsin-Ling Yang; Alan Yueh-Luen Lee; Ming-Tz Tsai; Zong-Lun Guo; Yu-Shan Cheng; Yin-Chang Liu; Yu-Hsuan Lan; Yu-Ching Chang; Ying-Chin Ko; Hsueh-Wei Chang; Yang-Chang Wu // BMC Cancer;2010, Vol. 10, Special section p1 

    Background: The crude extract of the fruit bearing plant, Physalis peruviana (golden berry), demonstrated antihepatoma and anti-inflammatory activities. However, the cellular mechanism involved in this process is still unknown. Methods: Herein, we isolated the main pure compound,...

  • OSI Pharmaceuticals begins application process for lung cancer drug.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p11 

    Reports that OSI Pharmaceuticals initiated the submission of a new drug application with the U.S. Food and Drug Administration for the use of Tarceva in the treatment of patients with incurable stage IIB/IV non-small cell lung cancer who have failed standard therapy for advanced metastic...

  • Downregulation of hnRNP K by RNAi inhibits growth of human lung carcinoma cells. FENGMING TANG; WEIMIN LI; YAN CHEN; DONGMEI WANG; JUAN HAN; DAN LIU // Oncology Letters;2014, Vol. 7 Issue 4, p1073 

    Lung cancer is one of the most common malignancies worldwide, but its pathogenesis remains unknown. The current study examined the effects of heterogeneous nuclear ribonucleoprotein K (hnRNP K)-targeted small interfering RNA (siRNA) on the growth and apoptosis of lung cancer cells in vitro. The...

  • Analysis of the Growth Control Network Specific for Human Lung Adenocarcinoma Cells. Pinna, G.; Zinovyev, A.; Araujo, N.; Morozova, N.; Harel-Bellan, A. // Mathematical Modelling of Natural Phenomena;Jan2012, Vol. 7 Issue 1, p337 

    Many cancer-associated genes and pathways remain to be identified in order to clarify the molecular mechanisms underlying cancer progression. In this area, genome-wide loss-of-function screens appear to be powerful biological tools, allowing the accumulation of large amounts of data. However,...

  • Financings Roundup.  // BioWorld Today;8/16/2011, Vol. 22 Issue 158, p7 

    The article reports that Lorus Therapeutics Inc. of Toronto, Canada completed its offering of 5.5 million units prices at 40Canadian cents apiece for a gross proceeds of 2.2 million Canadian dollars.

  • Lorus Therapeutics announces patent allowance for small molecule drugs.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p15 

    The article reports on the allowance of Lorus Therapeutics Inc.'s first patent in China for novel drug candidates from its small molecule program.

  • Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. Dong, Li-xia; Sun, Lin-lin; Zhang, Xia; Pan, Li; Lian, Lin-juan; Chen, Zhe; Zhong, Dian-sheng // Acta Pharmacologica Sinica;Feb2013, Vol. 34 Issue 2, p314 

    Aim:To investigate the role of LKB1 in regulation of mTOR signaling in non-small cell lung cancer (NSCLC) cells.Methods:LKB1 protein expression and phosphorylation of AMPK, 4E-BP1 and S6K in the cells were assessed using Western blotting in various NSCLC cell lines (A549, H460, H1792, Calu-1 and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics